TGF-beta-1 Levels and Heart Disease in Diabetic Patients
Author Information
Author(s): Beatriz D Schaan, Alexandre S Quadros, Rogério Sarmento-Leite, Giuseppe De Lucca Jr, Alexandra Bender, Marcello Bertoluci
Primary Institution: Institute of Cardiology of Rio Grande do Sul/University Foundation of Cardiology, Porto Alegre, Brazil
Hypothesis
Is there an association between serum TGF-β1 levels and coronary artery disease in diabetic patients?
Conclusion
Serum TGF-β1 was not associated with CAD or MACE occurrence in patients with or without diabetes.
Supporting Evidence
- Patients with CAD had a higher mean age and a higher percentage were male.
- TGF-β1 levels were similar across all patient groups.
- Independent predictors of 2-year MACE included age, C-reactive protein, and systolic blood pressure.
Takeaway
The study looked at whether a protein called TGF-beta-1 is linked to heart problems in people with diabetes, and it found that it isn't.
Methodology
Patients referred for coronary angiography were evaluated and classified into four groups based on diabetes and coronary artery disease status, followed for 2 years for major adverse cardiovascular events.
Potential Biases
Potential bias due to the high percentage of patients using aspirin, which may affect TGF-β1 levels.
Limitations
The study had a small sample size and could not stratify patients by age or CAD severity.
Participant Demographics
Mean age was 58.2 years, with 51% being men.
Statistical Information
P-Value
p = 0.547
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website